Pure Global
NCT05992896

A Study of Loco-Regional Liposomal Bupivacaine Injection

Can Loco-regional Anesthesia With Liposomal Bupivacaine Reduce Intra- and Post-operative Narcotic Use in Patients Undergoing Lower Extremity Revascularization? A Prospective, Triple Blinded, Randomized Trial.
Mayo Clinic·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral Arterial Disease
Drug/Device/Intervention
Bupivacaine liposome
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Eau Claire, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Sep 26, 2023
End date
Feb 01, 2024
Enrollment
20 participants
Primary outcome

Postoperative use of narcotics at 12 hours,Postoperative use of narcotics at 24 hours,Postoperative use of narcotics at 48 hours,Postoperative use of narcotics at 72 hours,Postoperative use of narcotics at 30 days

Summary

The purpose of this research is to find out if using liposomal bupivacaine solution
 (bupivacaine liposome) injections during lower extremity revascularization surgery will lower
 the amount of narcotic drugs used during and following the procedure.

ICD-10 classifications
Peripheral vascular disease, unspecifiedOther peripheral vascular diseasesOther specified peripheral vascular diseasesPeripheral angiopathy in diseases classified elsewhereOther congenital malformations of peripheral vascular system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05992896
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05992896 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.